Dr Reddys Laboratories (RDY) Return on Sales (2009 - 2023)

Dr Reddys Laboratories (RDY) posted quarterly Return on Sales of 0.0% for Q2 2023, down 3.19% quarter-over-quarter from 0.0% in Q1 2023.

Dr Reddys Laboratories (RDY) Return on Sales (2009 - 2023) Analysis & Trends

Dr Reddys Laboratories' Return on Sales history runs 15 years deep, the most recent figure standing at 0.0% for Q2 2023.

In Q2 2023, Return on Sales changed N/A year-over-year to 0.0%; the TTM figure through Jun 2023 stood at 0.0% (changed N/A YoY), while the FY2026 annual figure was 0.0%, changed 0.0% from the prior year.
Return on Sales for Q2 2023 stood at 0.0%, down from 0.0% in the prior quarter.
The five-year high for Return on Sales was 0.0% in Q1 2019, with the low at 0.0% in Q3 2020.
The 5-year median for Return on Sales is 0.0% (2020), against an average of 0.0%.
Peak annual rise in Return on Sales reached 0 bps in 2019, while the deepest fall reached 0 bps in 2019.
Dr Reddys Laboratories' Return on Sales stood at 0.0% in 2019, then tumbled by 244 bps to 0.0% in 2020, then jumped by 208 bps to 0.0% in 2021, then decreased by 12 bps to 0.0% in 2022, then soared by 35 bps to 0.0% in 2023.
Business Quant data shows RDY's Return on Sales at 0.0% in Q2 2023, 0.0% in Q1 2023, and 0.0% in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Haleon	43.65 Bn	42.68 Bn	-	-
2	Teva Pharmaceutical Industries	43.09 Bn	39.44 Bn	2.15 Bn	0.00%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	0.00%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	0.00%
5	United Therapeutics	22.11 Bn	19.45 Bn	683.80 Mn	0.00%
6	Viatris	18.77 Bn	17.88 Bn	1.46 Bn	0.00%
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	0.00%
8	Elanco Animal Health	12.07 Bn	11.54 Bn	798.00 Mn	0.00%
9	Dr Reddys Laboratories	10.09 Bn	9.93 Bn	-	-
10	Alkermes	8.20 Bn	7.54 Bn	397.90 Mn	0.00%

Download Data